Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Revolution Medicines (RVMD) Income from Continuing Operations (2019 - 2025)

Historic Income from Continuing Operations for Revolution Medicines (RVMD) over the last 7 years, with Q3 2025 value amounting to -$305.2 million.

  • Revolution Medicines' Income from Continuing Operations fell 9528.43% to -$305.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$960.9 million, marking a year-over-year decrease of 6945.81%. This contributed to the annual value of -$600.0 million for FY2024, which is 3750.95% down from last year.
  • As of Q3 2025, Revolution Medicines' Income from Continuing Operations stood at -$305.2 million, which was down 9528.43% from -$247.8 million recorded in Q2 2025.
  • In the past 5 years, Revolution Medicines' Income from Continuing Operations ranged from a high of -$37.2 million in Q1 2021 and a low of -$305.2 million during Q3 2025
  • Moreover, its 5-year median value for Income from Continuing Operations was -$98.3 million (2023), whereas its average is -$117.8 million.
  • As far as peak fluctuations go, Revolution Medicines' Income from Continuing Operations plummeted by 727.28% in 2022, and later crashed by 18587.08% in 2023.
  • Over the past 5 years, Revolution Medicines' Income from Continuing Operations (Quarter) stood at -$52.7 million in 2021, then decreased by 7.27% to -$56.5 million in 2022, then tumbled by 185.87% to -$161.5 million in 2023, then fell by 20.42% to -$194.5 million in 2024, then tumbled by 56.9% to -$305.2 million in 2025.
  • Its last three reported values are -$305.2 million in Q3 2025, -$247.8 million for Q2 2025, and -$213.4 million during Q1 2025.